HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma

HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma

Background Histone deacetylase (HDAC), a kind of protease that regulates gene expression by modifying protein acetylation levels, is usually aberrantly activated in tumors. The approved pan-HDAC inhibitors (HDACi) have exhibited clinical benefits for hematopoietic malignancies. Recently, HDACis have...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Yu, Yuan Fang, Yongqian Shu, Tong Hu, Tingting Xu, Duo Xu, Yunru Gu, Yang-Yue Xu, Hao-Yang Shen, Pei Ma
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e010077.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items